Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection

Pei‐Fen Zhang, Ziyi Wu, Wenbin Zhang, Yong‐Qiao He, Kexin Chen, Tong‐Min Wang, Haixin Li, Hong Zheng, Dan‐Hua Li, Dawei Yang, Ting Zhou, Changmi Deng, Ying Liao, Wen‐Qiong Xue, Lianjing Cao, Xi‐Zhao Li, Jiangbo Zhang, Siqi Dong, Fang Wang, Mei‐Qi Zheng, Wenli Zhang, Jianbing Mu, Wei‐Hua JiaNature Communications 2023 · DOI

Abstract

Various biomarkers targeting cell-free DNA (cfDNA) and circulating proteins have been tested for pan-cancer detection. Oncofetal chondroitin sulfate (ofCS), which distinctively modifies proteoglycans (PGs) of most cancer cells and binds specifically to the recombinant Plasmodium falciparum VAR2CSA proteins (rVAR2), is explored for its potential as a plasma biomarker in pan-cancer detection. To quantitate the plasma ofCS/ofCSPGs, we optimized an ELISA using different capture/detection pairs (rVAR2/anti-CD44, -SDC1, and -CSPG4) in a case-control study with six cancer types. We show that the plasma levels of ofCS/ofCSPGs are significantly higher in cancer patients (P values, 1.2 × 10<sup>-2</sup> to 4.4 × 10<sup>-10</sup>). Validation studies are performed with two independent cohorts covering 11 malignant tumors. The individuals in the top decile of ofCS-CD44 have more than 27-fold cancer risk (OR = 27.8, 95%CI = 18.8-41.4, P = 2.72 × 10<sup>-62</sup>) compared with the lowest 20%. Moreover, the elevated plasma ofCS-CD44 could be detected at the early stage of pan-cancer with strong dose-dependent odds risk prediction.

Introduction

Early detection remains the most effective strategy for reducing cancer-related mortality. However, conventional screening methods are often limited to specific organs and may lack the sensitivity required for early-stage diagnosis. While liquid biopsies utilizing cell-free DNA (cfDNA) have emerged as a promising "universal" screening tool, their clinical adoption is hindered by high costs and technical complexity.

This study investigates a glycobiology-based approach focusing on oncofetal chondroitin sulfate (ofCS). This specific carbohydrate modification is prevalent on the surface of malignant cells and placental tissue but is virtually absent in healthy adult tissues. The high specificity of ofCS makes it an ideal candidate for a pan-cancer biomarker.

Methods

The researchers leveraged the evolutionary mechanism used by the malaria parasite Plasmodium falciparum to adhere to the placenta. The parasite produces a protein, VAR2CSA, which binds specifically to ofCS.

Protein Engineering and Selection

The team engineered seven recombinant versions of the VAR2CSA protein (rVAR2) to identify variants with the highest binding affinity for cancer-derived ofCS. These variants were tested across multiple cancer cell lines to validate their binding specificity and dose-response characteristics.

Engineering and validation of rVAR2 variants for cancer cell binding. (a) Domain structures of rVAR2 variants. (b) Binding assays (MFI) across multiple cancer cell lines at varying concentrations.

ELISA Development

A specialized sandwich ELISA was developed to quantify ofCS-modified proteoglycans in plasma. The assay uses antibodies against common protein backbones (CD44, SDC1, or CSPG4) for capture and the optimized rVAR2 protein for the detection of the specific oncofetal sugar modification.

Results

The biomarker was rigorously validated across three distinct cohorts, culminating in a large-scale study of 13,735 participants covering 11 malignant tumor types.

Diagnostic Performance of ofCS-CD44

Among the candidates, ofCS-modified CD44 (ofCS-CD44) demonstrated the highest diagnostic accuracy. In the discovery set, it achieved an Area Under the Curve (AUC) of 0.84, maintaining a solid AUC of 0.73 in the massive 13,000+ person validation set.

Risk Correlation and Early Detection

A strong dose-dependent relationship was observed between plasma ofCS-CD44 levels and cancer risk. Individuals in the highest decile of ofCS-CD44 concentration had a 27.8-fold increased risk of cancer compared to those in the lowest 20% (OR = 27.8, 95% CI = 18.8–41.4). Notably, elevated ofCS-CD44 was detectable in patients with Stage I and II disease, suggesting its utility for early-stage screening.

Discussion

The study demonstrates that the "malaria connection"—repurposing a parasite protein for cancer detection—provides a robust method for identifying malignant biomarkers in blood plasma. ofCS-CD44 appears to be a stable and reliable indicator across a broad spectrum of solid tumors, particularly gastrointestinal and bladder cancers.

Despite these promising results, limitations include the inherent molecular heterogeneity of ofCS and the current lack of standardized synthetic materials for assay calibration. Future research will focus on longitudinal studies to evaluate the test's predictive power in asymptomatic populations and the potential for multi-analyte panels to further improve diagnostic precision.

Summary updated

Abstract

Various biomarkers targeting cell-free DNA (cfDNA) and circulating proteins have been tested for pan-cancer detection. Oncofetal chondroitin sulfate (ofCS), which distinctively modifies proteoglycans (PGs) of most cancer cells and binds specifically to the recombinant Plasmodium falciparum VAR2CSA proteins (rVAR2), is explored for its potential as a plasma biomarker in pan-cancer detection. To quantitate the plasma ofCS/ofCSPGs, we optimized an ELISA using different capture/detection pairs (rVAR2/anti-CD44, -SDC1, and -CSPG4) in a case-control study with six cancer types. We show that the plasma levels of ofCS/ofCSPGs are significantly higher in cancer patients (P values, 1.2 × 10<sup>-2</sup> to 4.4 × 10<sup>-10</sup>). Validation studies are performed with two independent cohorts covering 11 malignant tumors. The individuals in the top decile of ofCS-CD44 have more than 27-fold cancer risk (OR = 27.8, 95%CI = 18.8-41.4, P = 2.72 × 10<sup>-62</sup>) compared with the lowest 20%. Moreover, the elevated plasma ofCS-CD44 could be detected at the early stage of pan-cancer with strong dose-dependent odds risk prediction.
BibTeX
@inproceedings{zhang2023establishment,
  author = {Pei‐Fen Zhang and Ziyi Wu and Wenbin Zhang and Yong‐Qiao He and Kexin Chen and Tong‐Min Wang and Haixin Li and Hong Zheng and Dan‐Hua Li and Dawei Yang and Ting Zhou and Changmi Deng and Ying Liao and Wen‐Qiong Xue and Lianjing Cao and Xi‐Zhao Li and Jiangbo Zhang and Siqi Dong and Fang Wang and Mei‐Qi Zheng and Wenli Zhang and Jianbing Mu and Wei‐Hua Jia},
  title = {{Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection}},
  booktitle = {Nature Communications},
  year = {2023},
  doi = {10.1038/s41467-023-36374-7},
}
Figure